BioElectronics Corporation Korean FDA Approval for ActiPatch Achieved
FREDERICK, Md., Oct. 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that the by the Korean Food and Drug Administration has cleared ActiPatch for sale in Korea.
"We have been working closely with our distributor, YoungKwangSa Co., Ltd., to achieve the approval of the Korean F.D.A. Having worked so diligently to obtain the approvals, we are confident that YoungKwangSa is now poised to successfully launch ActiPatch in the Korean market. We expect to ship the initial stock order within the next 15 days," said Andrew Whelan, President of BioElectronics Corporation.
Marshal Nam of YoungKwangSa said "We are pleased to have achieved the clearance from the Korean FDA to begin importing the ActiPatch device. It was a long process and we worked cooperatively with BioElectronics Corporation to obtain the necessary approvals. We are excited to represent ActiPatch in Korea and expect to have a strong business relationship with BioElectronics Corporation for many years."
About YoungKwangSa Co., Ltd.:
Founded in 1971, YoungKwangSa has provided medical professionals in Korea with the most state-of-the art medical devices available. To learn more about YoungKwangSa please visit http://www.actipatch.co.kr.
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,
+1-866-757-2284, fax, +1-301-874-6935, info@actipatch.net
Web site: http://www.bioelectronicscorp.com/
http://www.actipatch.co.kr/